Abstract: Methods of using small molecule inhibitors of fatty acid oxidation (FAO) as antimicrobials against intracellular Mycobacteria are disclosed. FAO inhibitors including etomoxir, trimetazidine, oxfenicine perhexeline and/or can be used alone, or in combination with known as antimycobacterial agents against intracellular Mycobacteria.

Abstract: Methods of using small molecule inhibitors of fatty acid oxidation (FAO) as antimicrobials against intracellular Mycobacteria are disclosed. FAO inhibitors including etomoxir, trimetazidine, oxfenicine perhexeline and/or can be used alone, or in combination with known as antimycobacterial agents against intracellular Mycobacteria.

Abstract: An airship includes a ballonet, a ballonet tracking system, and a vehicle management system. The ballonet is disposed within the airship and includes a ballonet surface. The ballonet tracking system includes one or more light emitters disposed within the ballonet at one or more fixed locations and one or more light detectors disposed within the ballonet at the one or more fixed locations. The ballonet tracking system measures a plurality of distances between one or more fixed locations and one or more locations on the ballonet surface. The ballonet tracking system also calculates differences between a predetermined set of expected distances and the plurality of measured distances. Based on the calculated differences, the ballonet tracking system calculates a volume of the ballonet. The vehicle management system is communicatively coupled to the ballonet tracking system and controls the operation of the airship using the calculated volume of the ballonet.

Abstract: Methods of using small molecule inhibitors of fatty acid oxidation (FAO) as antimicrobials against intracellular Mycobacteria are disclosed. FAO inhibitors including etomoxir, trimetazidine, oxfenicine perhexeline and/or can be used alone, or in combination with known as antimycobacterial agents against intracellular Mycobacteria.

Abstract: An airship includes a ballonet, a ballonet tracking system, and a vehicle management system. The ballonet is disposed within the airship and includes a ballonet surface. The ballonet tracking system includes one or more light emitters disposed within the ballonet at one or more fixed locations and one or more light detectors disposed within the ballonet at the one or more fixed locations. The ballonet tracking system measures a plurality of distances between one or more fixed locations and one or more locations on the ballonet surface. The ballonet tracking system also calculates differences between a predetermined set of expected distances and the plurality of measured distances. Based on the calculated differences, the ballonet tracking system calculates a volume of the ballonet. The vehicle management system is communicatively coupled to the ballonet tracking system and controls the operation of the airship using the calculated volume of the ballonet.

Abstract: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(?O)2NR1— and —NR1S(?O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(?O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.

Abstract: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(?O)2NR1— and —NR1S(?O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(?O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.